Summary

Types of mito, summary icon - DNA affected icon

Type of DNA affected

Mitochondrial

Types of mito, summary icon - Types of mito, summary icon - Genetic change icon

Common genetic change

m.8344A>G

Types of mito, summary icon - Age of onset icon

Typical age of onset

Adolescence - adulthood

Types of mito, summary icon - Body area affected

Body area impacted

Brain, nerves and muscles

Summary

Types of mito, summary icon - DNA affected icon

Type of DNA affected

Mitochondrial

Types of mito, summary icon - Types of mito, summary icon - Genetic change icon

Common genetic change

m.8344A>G

Types of mito, summary icon - Age of onset icon

Typical age of onset

Adolescence - adulthood

Types of mito, summary icon - Body area affected

Body area impacted

Brain, nerves and muscles

Summary

Types of mito, summary icon - DNA affected icon

Type of DNA affected
Mitochondrial

Types of mito, summary icon - Types of mito, summary icon - Genetic change icon

Common genetic change
m.8344A>G

Types of mito, summary icon - Age of onset icon

Age of onset
Adolescence - adulthood

Types of mito, summary icon - Body area affected

Body area impacted
Brain, nerves and muscles

About MERRF

Myoclonic Epilepsy and Ragged-Red Fibres, most commonly known as MERRF, is a rare inherited genetic condition. It is one of at least 350 known types of mitochondrial disease (mito).

Mito affects the mitochondria, which are tiny parts inside our cells that help make the energy our bodies need. When mitochondria do not work as they should, some parts of the body may not have enough energy to work properly. In MERRF, the brain and the nervous system (encephalo-), skeletal muscles (myopathy) and other body systems are commonly affected.1,2

Signs and symptoms of MERRF usually start during late adolescence to adulthood but can occur at any age.1,3 The first sign is usually involuntary, sudden, and brief muscle movements known as myoclonus, followed by seizures, difficulty coordinating movement, weakness, and cognitive impairment.1,2

Prefer to listen?

Hear this information on our Audio Learning Channel.

Curious about mito?

For more information visit our Understanding mito page. You’ll find explanations about what mito is, its symptoms, its causes, and how it affects the body.

Speech bubble icon

Pronunciation

Myoclonic (Mai-uh-klo-nuhk) Epilepsy (eh-puh-lep-see) and Ragged-Red Fibres

Clipboard icon

Other names for MERRF

  • Myoclonic epilepsy associated with ragged red fibers
  • Fukuhara syndrome
  • Myoclonus epilepsy associated with ragged red fibers
  • Myoencephalopathy ragged-red fiber disease

MERRF may also be referred to as:

  • Mitochondrial disease
  • Primary Mitochondrial Disease (PMD)
  • Mitochondrial encephalopathy
Emergency ambulance icon

Planning for urgent care

If your mito specialist thinks you may get unwell quickly, they may give you an emergency plan. If you do not have a mito specialist, you could ask the specialist you see who knows about mito.

An emergency plan lists your diagnosis and care information from your care team. It can help to keep a copy with you. This could be on paper, on your phone or saved where you or your carer can find it fast. You can show the plan if you go to hospital, need an ambulance or see a new health professional. It can also help to keep current contact details for your main care team. This may include your general practitioner (GP), mito specialist or other specialist. You can also list other health professionals who know you well.

The Australian Patient Care Standards for mito and Important information about medicines can also help guide health professionals who are less familiar with mito.

Family icon

Dalia's story

Jessica Fein is the mum to three children living in the US. Her middle child, 16-year-old Dalia, has MERRF Syndrome. You can listen to Jessica back in 2021 when she was a guest on the Once Upon a Gene podcast (episode 107).

Beyond the basics

Learn more and find support to help you navigate your journey with mito.

Flag Icon Milestones

1973 - Doctors noticed a group of family members with similar symptoms, including epilepsy and muscle weakness. Muscle tests showed damaged muscle fibres, now called ragged-red fibres.4–6

1980 - More families with similar symptoms were found. This helped doctors understand that MERRF was its own condition. The name "MERRF" was first used.6

1981 - Scientists finished mapping the full human mitochondrial genome. This helped researchers study mito conditions like MERRF more closely.7

1990 - A major breakthrough: researchers found a genetic change in mitochondrial DNA that causes MERRF. This change, called m.8344A>G, affects how the body makes energy.8,9

Since 1990 - Other, less common gene changes have also been found. This shows that MERRF is not caused by just one single mutation.4

Globe Icon Prevalence
Symptoms Icon Symptoms
Flag Icon Causes
Diagnosis Icon Diagnosis
Care team Icon Care team
Health care Icon Health care
Clinical studies Icon Clinical studies
Support Icon Support groups

Mito Foundation support services

Helpline

Call Helpine for general advice, assistance in seeking a referral or more information on Mito Foundation support services.

Events

Mito Foundation events bring together people impacted by mitochondrial disease (mito).

NDIS support

Access the NDIS Navigation Service (NNS) for resources, education and 1:1 guidance on the NDIS.

Disclaimer: Resources provided by the Australian Mitochondrial Disease Foundation Limited (Mito Foundation), offers general information and is not a substitute for medical advice. It is essential to assess the suitability of the content for your individual circumstances and make decisions based on your medical condition. The information’s accuracy is subject to change, and we do not guarantee ongoing currency or availability. While efforts are made to ensure accuracy, Mito Foundation is not obligated to provide updated information. The copyright for this document and its content belongs to, or is licensed to, Mito Foundation, and reproduction without prior written consent is prohibited.

Acknowledgement: Mito Foundation acknowledges the valuable contributions of our reviewers, we thank Professor John Christodoulou AM MB BS PhD FRACP FRCPA FHGSA, and Dr Benjamin Kamien (Clinical Geneticist), for their review. As well as members of the mito community resource review panel.

Author: Mito Foundation 
Version: 1
Date published: Wednesday 6 August 2025